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Abstract Melanotransferrin (MTf) is a membrane-bound
transferrin (Tf) homologue that is found at high levels in
melanoma cells. MTf has many characteristics in common with
serum Tf and previous studies have shown that it can bind Fe.
This has led to speculation that MTf may be involved in Fe
transport. Because Fe is required for a variety of metabolic
reactions including ATP and DNA synthesis, MTf could play a
role in proliferation. However, recently it has been shown that
MTf plays very little role in Fe uptake by melanoma cells, and
unlike other Fe transport molecules (e.g. the transferrin
receptor), its expression is not controlled by Fe. In the present
review the function of MTf is discussed in relation to data
suggesting other roles apart from Fe uptake. ß 2000 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. General introduction
Iron (Fe) plays a crucial role in cellular metabolism as it is
essential for a wide variety of metabolic reactions upon which
life depends, including ATP and DNA synthesis. Indeed, it
has been suggested that Fe was an essential component for the
genesis of life (for review see [1]). Due to this vital require-
ment for Fe, cells developed a repertoire of Fe-binding and
transport proteins known as the transferrins [1]. The most well
known of these proteins is serum transferrin (Tf) which is
involved in Fe transport in the plasma. This molecule donates
its Fe to cells via its speci¢c binding to Tf receptors (TfRs)
present on the cell membrane (Fig. 1) [1]. The Tf is then
internalised by receptor-mediated endocytosis, the Fe is re-
leased from the protein within an endosome, and then trans-
ported into the cell to become part of the intracellular Fe
pool. The Fe may be used for a variety of crucial enzymes
such as ribonucleotide reductase or haem proteins and stored
in ferritin (Fig. 1) [1].
It was of great interest that in the early 1980s the ¢rst Tf-
like molecule was discovered [2^4]. This protein was initially
known as human melanoma antigen p97 since it was ¢rst
identi¢ed at high levels in malignant melanoma cells [2^4].
It was later called melanotransferrin due to its high homology
with Tf. The properties shared between human MTf and Tf
include: (i) it has 37^39% sequence homology with human
serum Tf, human lactoferrin, and chicken Tf; (ii) the MTf
gene is on chromosome 3, as are those for Tf and the TfR;
(iii) many of the disulphide bonds present in serum Tf and
lactoferrin are also present in MTf; (iv) MTf has an N-termi-
nal Fe-binding site that is very similar to that found in serum
Tf, while the C-terminal is di¡erent and does not bind Fe;
and (v) isolated and puri¢ed MTf can bind Fe from Fe(III)^
citrate complexes [2^7]. These observations appeared to indi-
cate that MTf plays a role in Fe transport.
The most obvious di¡erence between MTf and serum Tf is
that Tf circulates in the plasma, while MTf is bound to the
cell membrane by a glycosyl phosphatidylinositol (GPI) an-
chor [8,9]. Indeed, MTf can be removed speci¢cally from the
cell membrane using phosphatidylinositol-speci¢c phospholi-
pase C (PI-PLC [8^10]). Apart from the membrane-anchored
form, MTf can also be secreted, and this is not just due to
passive partitioning from the membrane into the medium
[8,9]. The function of secretory MTf remains unclear and
largely unexplored.
2. Can human melanotransferrin transport iron?
Initial studies in the early 1990s examined the relative roles
of MTf compared to the TfR in Fe uptake by the human
melanoma cell line SK-Mel-28 [11^15]. This cell line was
used because it expresses the highest levels of MTf of all
cell types tested (3^3.8U105 MTf sites/cell [2]). The SK-Mel-
28 melanoma cell incorporates Fe from Tf by two processes
consistent with receptor-mediated endocytosis and pinocytosis
of Tf [11,12,15]. In addition, these cells take up Fe from low-
Mr Fe complexes by a TfR-independent process [13]. Of in-
terest, a membrane-bound, protease-sensitive, Fe-binding
component was identi¢ed in SK-Mel-28 cells consistent with
MTf [11^13]. However, while this membrane Fe-binding com-
ponent could bind Fe, it did not appear to donate it to the cell
[12,13].
Further studies using Chinese hamster ovary (CHO) cells
transfected with MTf [10] showed that this molecule could
transport Fe derived from 59Fe^citrate complexes but not
Tf. However, the levels of MTf (1.2U106 sites/cell [10]) in
transfected cells were 3^4-fold greater than that found on
the SK-Mel-28 cell line (3^3.8U105 sites/cell [2]). Because Fe
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uptake from 59Fe^citrate by MTf-transfected CHO cells was
only 2.4-fold that of control CHO cells after a 4 h label [10],
these data questioned the role of MTf in the Fe uptake pro-
cess of melanoma cells where it was expressed at lower levels
[1].
Considering these latter results, further experiments were
designed to characterise the pathophysiological role of MTf
in Fe uptake by the SK-Mel-28 melanoma cell. Initial studies
examined if modulation of intracellular Fe levels using the Fe
chelator desferrioxamine (DFO) or the Fe source ferric am-
monium citrate (FAC) could change MTf mRNA levels.
Under conditions of Fe depletion, up-regulation of the TfR
increases Fe uptake from Tf which corrects the de¢ciency,
while down-regulation of TfR levels occurs when intracellular
Fe concentration increases [1]. In contrast to TfR mRNA that
increases after exposure to DFO and decreases after incuba-
tion with FAC, there was no change in MTf mRNA levels. In
addition, compared to control cells, there was no alteration of
125I-labelled anti-MTf monoclonal antibody (mAb) binding in
cells exposed to DFO or FAC, suggesting no change in the
number of MTf sites. Further studies examined the ability of
DFO and FAC to modulate Fe uptake from 59Fe^citrate
which is bound by MTf [3,10,13]. In contrast to the expected
e¡ect of DFO or FAC at increasing and decreasing Fe uptake
from 59Fe^Tf respectively [1], DFO had no in£uence on 59Fe^
citrate uptake, whereas FAC markedly increased it. Collec-
tively, these studies suggest that MTf was not regulated like
the TfR in response to cellular Fe levels [16]. Indeed, if MTf
were a crucial transporter of Fe for cellular metabolism, it
may be expected that its regulation would be comparable to
the TfR [16]. Regulation of Fe uptake is essential as Fe is vital
for cellular metabolism and its depletion can lead to death.
On the other hand, Fe overload can be toxic. These data
demonstrating no change in MTf expression after manipula-
tion of intracellular Fe levels are supported by previous im-
munohistochemical studies in the liver, showing that MTf ex-
pression did not alter in Fe overload disease in contrast to Tf
and the TfR [17].
Fig. 1. Schematic illustration demonstrating the role of the Fe-binding protein Tf in Fe uptake and the possible roles of MTf. The Tf in the se-
rum binds to the TfR on the cell membrane which is then internalised by receptor-mediated endocytosis. Once the Fe is released from Tf it
passes through the endosomal membrane by the Fe transporter Nramp2. The Fe then enters a poorly characterised compartment known as the
intracellular Fe pool. Iron in the pool is used for the synthesis of important Fe-containing proteins or can be stored in the Fe-storage protein
ferritin (see Section 1). MTf is found bound to the cell surface by a phosphatidylinositol anchor and does not play a signi¢cant role in Fe up-
take by melanoma cells where it is expressed at very high levels (see Section 2). The possible functions of MTf may include: (1) prevention of
free radical production and membrane damage by acting as an Fe scavenger, (2) cell surface metalloprotease, or (3) intercellular adhesion (via
docking with the TfR on other cell types) (see Section 5).
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As described above, MTf can be removed from the mem-
brane by PI-PLC [8^10]. Preincubation of melanoma cells
with PI-PLC reduced anti-MTf mAb binding to 3% of the
control, while PI-PLC only slightly reduced 59Fe uptake
from 59Fe^citrate [16]. These results suggest that MTf played
little role in Fe uptake from 59Fe^citrate by these cells [16].
Using a similar experimental protocol, more recent studies
have also demonstrated that depletion of MTf from HeLa
cell membranes had little e¡ect on Fe uptake from Fe^citrate
[18].
The results demonstrating ¢rst that MTf is not regulated by
Fe like the TfR, and second that PI-PLC treatment does not
lead to a marked decrease in Fe uptake from Fe^citrate, sug-
gest that MTf may not play a major role in Fe uptake by
these cells [16]. Indeed, it was previously shown that SK-Mel-
28 cells avidly take up Fe from Tf [11,15]. Moreover, MTf is
not involved in Fe uptake from Tf [10,13], which is the major
form of Fe in the circulation (for reviews see [1]).
Other evidence suggesting that MTf is not crucial for Fe
uptake include that it is not found in all melanoma cell lines,
varying from 0.3 to 80% of that found for SK-Mel-28 mela-
noma cells [19]. In addition, MTf expression has not been
consistently found on other rapidly growing cancer cells or
normal tissues [20]. Furthermore, while TfR numbers increase
prior to DNA synthesis [42], due to the Fe requirement of
ribonucleotide reductase [21], MTf density remains constant
throughout the cell cycle [22]. Seligman et al. [23] have shown
by mAb-binding studies in HL-60 leukemic cells and FAMC
110 melanoma cells that there is no change in MTf expression
between con£uent cells, growing cells, or cells grown in high
Tf concentrations. Therefore, these data again suggest that
MTf is not vital for obtaining Fe [1,12,13]. It cannot be com-
pletely discounted that in contrast to neoplastic cells, MTf in
normal resting cells could play some role in Fe internalisation.
Indeed, MTf could act as an Fe scavenger to inhibit mem-
brane lipid peroxidation and this is discussed further in Sec-
tion 6.1. However, more work is required to investigate this
possibility.
MTf was initially described as an oncofoetal antigen be-
cause it was found at high levels in tumours and foetal tissues
and was either not expressed or only slightly expressed in
normal tissues [19,24]. More recently, there have been reports
of human MTf being identi¢ed in normal tissues, including
sweat gland ducts [8,25], liver endothelial cells [8,17], and the
endothelium and reactive microglia of the brain [26,27]. In
addition, normal sera contained very low levels of MTf [28].
The expression of MTf mRNA (poly(A)) has also been ex-
amined amongst 50 human tissues and was found to be mark-
edly di¡erent than Tf mRNA or TfR mRNA [16]. Surpris-
ingly, MTf mRNA expression was widespread in normal
tissues, and was observed at its highest levels in the salivary
gland. In contrast to expectations, MTf mRNA expression
was generally greater in adult rather than foetal tissues [16],
which is di¡erent to that previously reported [19,24,28]. Last,
the high expression of MTf in the proximal kidney tubule [29],
salivary gland [16], and sweat gland ducts [8,25] argues against
a role in Fe transport, since Fe is never actively excreted and
remains tightly bound to Tf [30].
Considering all of the data collectively, it could be sug-
gested that MTf may play additional roles separate to its
ability to bind Fe.
3. Melanotransferrin and the brain
There have been some data indicating that MTf may play a
role in the brain. In a number of reports Je¡eries and asso-
ciates have shown that reactive microglia associated with the
amyloid plaques in brains of patients with Alzheimer’s disease
express MTf [26,31]. From these results it has been suggested
that the increased levels of MTf in the cerebrospinal £uid and
serum of Alzheimer’s disease patients [32] originate from the
reactive microglia associated with the senile plaques [31].
Apart from the reactive microglia, MTf was also expressed
in the capillary endothelium of the brain and had a distribu-
tion similar to that found for the TfR [26,27]. The role of MTf
in the brain remains unclear and further studies are essential
in order to de¢ne its function.
4. Other physiological roles of transferrin homologues
Apart from MTf, other Tf homologues have also been iden-
ti¢ed with physiological roles unrelated to Fe transport. These
include saxiphilin (a neurotoxin inhibitor), pacifastin (a pro-
teinase inhibitor) and the porcine inhibitor of carbonic anhy-
drase (pICA). The Tf homologue saxiphilin from the bullfrog
Rana catesbeiana contains two Tf lobes with high homology
to serum Tf (51% homology to frog serum Tf). However, this
molecule does not have Fe-binding activity, as most of the
critical Fe-coordinating amino acids are not conserved [33].
Instead of binding Fe, saxiphilin binds saxitoxin, a neurotoxin
produced by various cyanobacteria and dino£agellates [33].
The heavy chain of the protein pacifastin from the plasma
of cray¢sh, Pacifastacus leniusculus, is a Tf homologue that
acts as a proteinase inhibitor [34]. Pacifastin contain two co-
valently linked subunits, a heavy chain which is the Tf homo-
logue, and a light chain with proteinase inhibitory activity.
The proteinase inhibitory e¡ects of pacifastin require the Tf
heavy chain for activity [34]. Interestingly, the heavy chain
retains its ability to bind Fe, and it has 33% sequence homol-
ogy with cockroach Tf and human MTf. However, no evi-
dence has been presented to indicate that pacifastin plays a
role in serum Fe transport [34].
The porcine Tf homologue pICA (65% homology with por-
cine serum Tf) is found in serum and functions as an inhibitor
of carbonic anhydrase (CA) [35]. The ability of this molecule
to inhibit carbonic anhydrase appears to be its main function,
with little evidence of an Fe-transport role [35]. Despite the
high degree of similarity, pICA is functionally and biochemi-
cally di¡erent from the Tfs. All other Tfs tested failed to bind
or inhibit CA and they are antigenically distinct [35]. Hence,
considering these examples and the lack of any Fe transport
role of MTf in melanoma cells, it would not be unexpected
that MTf plays other biological roles.
At this point it is of interest to note that the polypeptide
motifs essential for binding metals apart from Fe show similar
evolutionary trends to other functions. For example, the
heavy chain of mammalian inter K-trypsin inhibitor has sig-
ni¢cant similarity to the multicopper-binding domain in the
group of multicopper oxidase proteins [36]. It can be specu-
lated that the evolution of proteins capable of binding essen-
tial metal ions for metabolism and growth in simple organ-
isms may have preceded other proteins with more specialised
roles. Perhaps the existing sca¡olding provided by the genetic
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code of primitive metal-binding proteins provided a conven-
ient framework for building other molecules.
With regard to possible other functional roles for MTf sep-
arate from Fe uptake, it is relevant to discuss that protein
sequence conservation in di¡erent organisms does not always
translate into the same physiological role in eukaryote metal
metabolism. This phenomenon is observed in the Arabidopsis
Fe transporter Irt1p, where its conserved counterpart in
the yeast is a Zn transporter, ZRT1 [37]. Similarly, the
human Nramp2 Fe transporter (also known as the divalent
metal ion transporter, DMT1) only shows strong homology
to yeast manganese transporters Smf1p and Smf2p, and
not the yeast Ftr1p (high-a⁄nity) or Fet4p (low-a⁄nity)
Fe transporters [38]. These data suggest that conserved
metal binding and sequence similarity of shared polypeptide
motifs are not always a su⁄cient determinant of physiological
role.
5. Melanotransferrin homologues ^ clues to functions apart
from iron transport?
To date MTf has been identi¢ed in the rabbit (GenBank
accession number AB010995), mouse (GenBank AB024336),
and chicken (GenBank X91908), with no evidence to suggest
high-a⁄nity Fe binding and transport as a primary function.
Indeed, in contrast to human, mouse, and rabbit MTfs that
have conserved Fe-binding residues (Asp, Tyr, Arg, Tyr and
His) in their N-terminal domain (but not in the C-terminus;
see Table 1), chicken MTf contains a substitution that may
prevent Fe binding (Table 2). Hence, chicken MTf with atyp-
ical N- and C-termini appears to have evolved away from
high-a⁄nity Fe binding [8]. Apart from this di¡erence, human
MTf and MTfs from chicken, rabbit, and mouse show several
common properties including: (i) a much higher sequence
identity or homology between themselves compared to other
Table 1
Comparison of the iron- and anion-coordinating amino acids present in MTfs, MTf homologues and other transferrins
Protein Source N-terminal repeat
(position of each amino acid)
C-terminal repeat
(position of each amino acid)
Melanotransferrins Human DYRYH (78,107,136,210,279)a SYSYH (421,451,482,556,625)
Chicken DYRYR (77,106,135,209,278) GYRYQ (420,450,481,555,624)
Rabbit DYRYH (78,107,136,210,279) NYSDH (421,451,482,556,625)
Mouse DYRYH (78,107,136,210,279) RYSYH (421,451,482,556,625)
Drosophila CG10620 DYSYD (93,121,153,231,295) DYTHN (505,533,563,640,709)
Drosophila CG3666 TYLYP (85,114,144,228,294) DYGDG (426,453,483,529,597)
Transferrins
Serum transferrinb Human DYRYH (82,114,143,207,268) DYRYH (411,445,475,536,604)
Lactotransferrinc Human DYRYH (80,112,140,212,273) DYRYH (415,455,485,548,617)
Transferrin Cockroach DYRYQ (78,111,141,225,295) DYRYH (429,457,487,573,642)
GenBank accession numbers (protein ID): human MTf ^ NP_005920; chicken MTf ^ CAA63003; rabbit ^ BAA33956; mouse ^ BAA86655;
Drosophila (CG10620) ^ AAF49900; Drosophila (CG3666) ^ AAF58039; human serum Tf ^ NP_001054; human Lf ^ NP_002334; cockroach
Tf ^ A47275.
aIn parentheses are positions of each iron-coordinating amino acid in the protein sequence.
bInvariant in human, rabbit, bovine, porcine, equine and chicken serum transferrin.
cInvariant in human, bovine and murine lactoferrin.
Table 2
Comparison of the active site of putative Zn2-dependent peptidases in standard one-letter amino acid symbols and the suggested site in human
and other melanotransferrins
Peptidase Sequence GenBank accession number Protein ID.
E-24.11 (human) 582IGHEITHGFD591 P08473
E-24.11 (rat) 582IGHEITHGFD591 P07861
E-24.11 (rabbit) 582IGHEITHGFD591 P08049
Fibroblast collagenase (human) 216AAHELGHSLG225 NP_002412
Stromelysin (human) 216AAHEIGHSLG225 AAB36942
Gelatinase (human) 411AAHEFGHAMG420 A28153
Aminopeptidase N (human) 386IAHELAHQWF395 CAA31640
Surface protease gp63 (Leishmania) 259VTHEMAHALG268 AAB96339
Neutral protease (Bacillus subtilis) 362TAHEMTHGVT371 BAA01604
Neutral protease (Serratia sp.) 174FTHEIGHALG183 999638
Peptidase N (Escherichia coli) 295IGHEYFHNWT304 AAA24317
Thermolysin (Bacillus stearothermophilus) 370VGHELTHAVT379 S72175
Aminopeptidase A 391VAHELVHQWF400 NP_001968
Leukotriene A4 hydrolase 294IAHEISHSWT303 NP_000886
TRH-degrading enzyme 438IVHEICHQWF447 NP_037513
Neutral endopeptidase 582IGHEITHGFD591 NP_009220
Angiotensin-converting enzyme 412AHHEMGHIQY421 P22966
Human MTf 344LGHEYLHAMK353 NP_005920
Mouse MTf 344LGQEYLQAMK353 BAA86655
Chicken MTf 343LGDEYLHGMQ352 CAA63003
Rabbit MTf 344LGPEYLHAMK353 BAA33956
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Tf family members; (ii) the conservation of all 28 cysteine
residues suggesting similar protein folding and tertiary struc-
ture; (iii) all four MTfs are anchored to the plasma membrane
by GPI anchors [9,29,39,40].
The identi¢cation of MTf in other species has suggested a
variety of functions. For example, in the mouse and rabbit,
the major site of MTf expression is on the cell surface of
chondrocytes, and it has been suggested that it is involved
in the control of chondrocyte di¡erentiation [39,40]. Similarly,
chicken MTf may in£uence eosinophil di¡erentiation, as the
gene is a direct target of the GATA-1 and C/EBPL transcrip-
tion factors that are responsible for the di¡erentiation of eo-
sinophils [29].
Recently the genome of Drosophila melanogaster has been
sequenced [41], and two genes were identi¢ed with sequences
indicating they are homologues of human MTf [41]. Based
upon the homology between vertebrate MTf and the £y ho-
mologues, the authors describe that these molecules could
mediate the main Fe uptake pathway in the £y [41]. The
article states that there is conservation of the residues in these
two proteins that are essential for Fe binding, and it is con-
cluded that the £y MTfs appear to be a ancestral mechanism
involved in Fe uptake [41].
However, comparing the £y MTf sequences to the consen-
sus Fe-binding residues required for Fe binding in the Tf
family, the critical Fe coordinating amino acids DYRYH
[42,43] were not conserved (Table 1). For instance, in the £y
MTf-like molecule (CG10620; GenBank AAF49900), there
are two changes in the consensus Fe-binding sequences in
the N-terminus (R to S and H to D) and three changes in
the consensus Fe-binding sequences in the C-terminus (R to
T, Y to H, and H to N; Table 1). In the second £y MTf
(CG3666; GenBank AAF58039), there are three changes
in the consensus Fe-binding sequences in the N-terminus
(D to T, R to L and H to P) and three changes in the
consensus Fe-binding sequences in the C-terminus (R to G,
Y to D and H to D; Table 1). These changes are important,
as minor alterations in the critical Fe-coordinating residues
can markedly in£uence Fe binding [42,43]. For example, the
C-terminal domain of human MTf is unable to bind Fe be-
cause of changes in two of the ¢ve Fe-binding residues [7].
Considering these changes, it is unlikely that the £y MTfs
would mediate Fe uptake in the same way as Tfs with con-
sensus Fe-binding domains. Indeed, even with a conserved
N-terminal Fe-binding site, MTf plays little role in Fe uptake
by melanoma cells [16] where it is expressed at very high levels
[2,3].
The high conservation of MTf but not its Fe-binding sites
in organisms with diverse evolutionary backgrounds again
suggests that this molecule plays an important role separate
from its ability to bind Fe. The possible biological roles of
MTf are discussed below.
6. Possible functional roles of melanotransferrin
The three sections below discuss possible roles of MTf
based upon preliminary evidence. Obviously, further investi-
gation is essential in terms of clearly de¢ning its biological
role.
6.1. Protection against membrane-lipid peroxidation
Discussing multiple roles of Tf homologues, it is of interest
to note that serum Tf itself plays a number of roles in the
organism. For instance, it is the main protein involved in Fe
transport in the plasma, and in relation to this, it also has a
protective function via its binding of low-Mr Fe which pre-
vents toxic free radical production [1,30]. Through its roles of
binding Fe, Tf also has a bacteriostatic function against some
microbes, as Fe is essential for their growth [30]. If MTf has a
protective role, and considering that it is membrane-bound, it
may act as a capture and hold mechanism to prevent toxic
free Fe deposition on membranes. Alternatively, MTf may
limit the presence of excessive amounts of free Fe released
from damaged tissues. In some pathological situations where
there is cell death, Fe is probably released, and MTf may act
to bind this and prevent lipid peroxidation Indeed, MTf has
an Fe-binding site that is very similar to that found in Tf and
can bind Fe from low-Mr complexes such as Fe(III)^citrate
[3,4,7]. Considering this, while previous studies have demon-
strated that MTf does not play a signi¢cant role in Fe inter-
nalisation by melanoma cells, a membrane-bound Fe-binding
component was identi¢ed that was consistent with MTf
[11,12].
6.2. Metalloprotease activity
Elegant molecular modelling studies have demonstrated
that a potential Zn(II)-binding thermolysin consensus se-
quence in MTf is oriented in an appropriate stereochemical
arrangement to allow it to bind Zn(II) that is crucial for
metalloprotease activity [44]. Indeed, the Zn-binding site re-
sponsible for catalytic activity in thermolysin is nearly super-
imposable on the MTf site [44]. Examining the MTf molecules
found in a variety of species, only human MTf contains the
consensus sequence HEXXH found in metallopeptidases such
as thermolysin (Table 2). This was a surprising ¢nding, and
could suggest that MTf found in other species could have
functions apart from metalloprotease activity.
6.3. Intercellular adhesion molecule
The high homology of MTf with serum Tf [4] suggests that
it could bind to the TfR. Indeed, there has been a preliminary
unrefereed conference report indicating that isolated MTf can
bind to the TfR [45]. Considering these data, it is important to
determine whether this interaction may be important in terms
of intercellular adhesion. For example, MTf bound on one
cell could interact with the TfR on another, e¡ectively acting
as a ‘key and lock’ mechanism and aiding intercellular dock-
ing. It can be hypothesised that this docking may target MTf
metalloprotease action to the sites of invasion. Indeed, such a
protease-docking function would not be unusual, as integrins
have been proposed to act in this way, forming invadopodia
[46].
7. Conclusions
Membrane-bound MTf does not play a signi¢cant role in
the uptake of Fe from low-Mr Fe complexes or Tf, suggesting
that it may have other unexpected roles. Indeed, this is sug-
gested by its di¡erent tissue distribution to Tf and the TfR
that is the major Fe uptake pathway. Considering other roles
of MTf, it is of interest that the Tf molecule appears to be an
ancient but useful sca¡old upon which to build a number of
di¡erent proteins with a variety of functions. While the role of
MTf remains speculative at present, further studies using
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knock-out animals are essential in order to understand the
role of this interesting molecule.
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